

# Thomas F Patterson

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6947579/thomas-f-patterson-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

107  
papers

21,332  
citations

47  
h-index

132  
g-index

132  
ext. papers

24,572  
ext. citations

8.6  
avg, IF

6.11  
L-index

#	Paper	IF	Citations
107	Coronavirus Disease 2019-Associated Invasive Fungal Infection. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab510	1	10
106	Aspergillus Polymerase Chain Reaction-An Update on Technical Recommendations, Clinical Applications, and Justification for Inclusion in the Second Revision of the EORTC/MSGERC Definitions of Invasive Fungal Disease. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, S95-S101	11.6	6
105	Evaluation of Sex Differences in Murine Diabetic Ketoacidosis and Neutropenic Models of Invasive Mucormycosis. <i>Journal of Fungi (Basel, Switzerland)</i> , <b>2021</b> , 7,	5.6	2
104	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. <i>Intensive Care Medicine</i> , <b>2021</b> , 47, 819-834	14.5	30
103	Aspergillosis: Epidemiology, Diagnosis, and Treatment. <i>Infectious Disease Clinics of North America</i> , <b>2021</b> , 35, 415-434	6.5	12
102	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. <i>Lancet Infectious Diseases, The</i> , <b>2021</b> , 21, e149-e162	25.5	242
101	Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. <i>Lancet Infectious Diseases, The</i> , <b>2021</b> , 21, e246-e257	25.5	40
100	SARS-CoV-2 spike-specific memory B cells express markers of durable immunity after non-severe COVID-19 but not after severe disease <b>2021</b> ,		1
99	SARS-CoV-2 spike-specific memory B cells express higher levels of T-bet and FcRL5 after non-severe COVID-19 as compared to severe disease.. <i>PLoS ONE</i> , <b>2021</b> , 16, e0261656	3.7	1
98	Open-Label Crossover Oral Bioequivalence Pharmacokinetics Comparison for a 3-Day Loading Dose Regimen and 15-Day Steady-State Administration of SUBA-Itraconazole and Conventional Itraconazole Capsules in Healthy Adults. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	11
97	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. <i>Intensive Care Medicine</i> , <b>2020</b> , 46, 1524-1535	14.5	149
96	Invasive Aspergillosis as an Under-recognized Superinfection in COVID-19. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, ofaa242	1	43
95	Fungal Infections Potentiated by Biologics. <i>Infectious Disease Clinics of North America</i> , <b>2020</b> , 34, 389-411	6.5	7
94	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 1367-1376	11.6	607
93	New Concepts in Diagnostics for Invasive Mycoses: Non-Culture-Based Methodologies. <i>Journal of Fungi (Basel, Switzerland)</i> , <b>2019</b> , 5,	5.6	16
92	Extended-Interval Dosing of Rezafungin against Azole-Resistant <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	14
91	Current Concepts and Future Directions in the Pharmacology and Treatment of Coccidioidomycosis. <i>Medical Mycology</i> , <b>2019</b> , 57, S76-S84	3.9	19

90	Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 757-763	5.1	26
89	Screening a Repurposing Library for Inhibitors of Multidrug-Resistant <i>Candida auris</i> Identifies Ebselen as a Repositionable Candidate for Antifungal Drug Development. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	49
88	Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important fungi. <i>Virulence</i> , <b>2017</b> , 8, 138-142	4.7	49
87	Modified release itraconazole amorphous solid dispersion to treat <i>Aspergillus fumigatus</i> : importance of the animal model selection. <i>Drug Development and Industrial Pharmacy</i> , <b>2017</b> , 43, 264-274 <sup>3.6</sup>		5
86	Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by <i>Aspergillus</i> and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. <i>Lancet, The</i> , <b>2016</b> , 387, 760-9	4.0	501
85	Invasive Aspergillosis: Current Strategies for Diagnosis and Management. <i>Infectious Disease Clinics of North America</i> , <b>2016</b> , 30, 125-42	6.5	67
84	Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 63, e1-e60	11.6	1274
83	Comparison of Nonculture Blood-Based Tests for Diagnosing Invasive Aspergillosis in an Animal Model. <i>Journal of Clinical Microbiology</i> , <b>2016</b> , 54, 960-6	9.7	17
82	Effect of Antifungal Treatment in a Diet-Based Murine Model of Disseminated Candidiasis Acquired via the Gastrointestinal Tract. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 6703-6708	5.9	11
81	The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 7115-7127	5.9	50
80	Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 63, 433-42	11.6	216
79	<i>Aspergillus</i> Polymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison With Antigen Testing. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 61, 1293-303	11.6	130
78	Emergence of Azole Resistance in <i>Aspergillus</i> . <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2015</b> , 36, 673-80	3.9	38
77	Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: a collaborative study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 60, 713-20	11.6	62
76	What's new in antifungals: an update on the in-vitro activity and in-vivo efficacy of new and investigational antifungal agents. <i>Current Opinion in Infectious Diseases</i> , <b>2015</b> , 28, 539-45	5.4	15
75	<i>Aspergillus</i> Species <b>2015</b> , 2895-2908.e4		1
74	Aspergillosis <b>2015</b> , 129-140		
73	Our 2014 approach to breakthrough invasive fungal infections. <i>Mycoses</i> , <b>2014</b> , 57, 645-51	5.2	27

72	Diagnosis and treatment of invasive fungal infections in the cancer patient: recent progress and ongoing questions. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 59 Suppl 5, S356-9	11.6	12
71	Animal Models In Mycology: What Have We Learned Over The Past 30 Years. <i>Current Fungal Infection Reports</i> , <b>2013</b> , 7, 68-78	1.4	6
70	Development and evaluation of a calibrator material for nucleic acid-based assays for diagnosing aspergillosis. <i>Journal of Clinical Microbiology</i> , <b>2013</b> , 51, 2403-5	9.7	21
69	Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2013</b> , 57, 3340-7	5.9	44
68	Prophylactic efficacy of single dose pulmonary administration of amphotericin B inhalation powder in a guinea pig model of invasive pulmonary aspergillosis. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2012</b> , 67, 970-6	5.1	17
67	Fungal disease of the nose and paranasal sinuses. <i>Journal of Allergy and Clinical Immunology</i> , <b>2012</b> , 129, 321-6	11.5	87
66	Assessment of <i>Aspergillus fumigatus</i> in guinea pig bronchoalveolar lavages and pulmonary tissue by culture and realtime polymerase chain reaction studies. <i>International Journal of Molecular Sciences</i> , <b>2012</b> , 13, 726-36	6.3	1
65	A murine model of <i>Cryptococcus gattii</i> meningoencephalitis. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2012</b> , 67, 1432-8	5.1	22
64	Detection and measurement of fungal burden in a guinea pig model of invasive pulmonary aspergillosis by novel quantitative nested real-time PCR compared with galactomannan and (1,3)- $\beta$ -D-glucan detection. <i>Journal of Clinical Microbiology</i> , <b>2012</b> , 50, 602-8	9.7	28
63	Detection of urinary excreted fungal galactomannan-like antigens for diagnosis of invasive aspergillosis. <i>PLoS ONE</i> , <b>2012</b> , 7, e42736	3.7	45
62	Invasive non- <i>Aspergillus</i> mold infections in transplant recipients, United States, 2001-2006. <i>Emerging Infectious Diseases</i> , <b>2011</b> , 17, 1855-64	10.2	209
61	Pulmonary aspergillosis: recent advances. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2011</b> , 32, 673-81	3.9	33
60	Caspofungin dose escalation for invasive candidiasis due to resistant <i>Candida albicans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 3254-60	5.9	51
59	Clinical utility and development of biomarkers in invasive aspergillosis. <i>Transactions of the American Clinical and Climatological Association</i> , <b>2011</b> , 122, 174-83	0.9	11
58	Aspergillosis <b>2011</b> , 243-263		
57	Factors associated with mortality in transplant patients with invasive aspergillosis. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 50, 1559-67	11.6	223
56	Efficacy of posaconazole as treatment and prophylaxis against <i>Fusarium solani</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>2010</b> , 54, 1055-9	5.9	18
55	Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. <i>Clinical Infectious Diseases</i> , <b>2010</b> , 50, 1091-100	11.6	991

54	Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). <i>Clinical Infectious Diseases</i> , <b>2010</b> , 50, 1101-11	11.6	1048
53	Aspergillus Species <b>2010</b> , 3241-3255		8
52	Risk stratification for invasive aspergillosis: early assessment of host susceptibility. <i>Medical Mycology</i> , <b>2009</b> , 47 Suppl 1, S255-60	3.9	23
51	Posaconazole therapeutic drug monitoring: a reference laboratory experience. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 2223-4	5.9	79
50	Case records of the Massachusetts General Hospital. Case 22-2009. A 59-year-old man with skin and pulmonary lesions after chemotherapy for leukemia [corrected]. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 287-96	59.2	14
49	Comparison of lateral flow technology and galactomannan and (1->3)-beta-D-glucan assays for detection of invasive pulmonary aspergillosis. <i>Vaccine Journal</i> , <b>2009</b> , 16, 1844-6		41
48	Immune reconstitution inflammatory syndrome after cessation of the tumor necrosis factor alpha blocker adalimumab in cryptococcal pneumonia. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2009</b> , 64, 327-30	2.9	29
47	Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. <i>Clinical Infectious Diseases</i> , <b>2008</b> , 46, 1813-21	11.6	3744
46	Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , <b>2008</b> , 46, 327-60	11.6	2097
45	Tratamiento de la Aspergilosis: Guías para la práctica clínica de la Sociedad de Enfermedades Infecciosas de los Estados Unidos de América (IDSA). <i>Clinical Infectious Diseases</i> , <b>2008</b> , 46, T1-T36	11.6	2
44	Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. <i>Clinical Infectious Diseases</i> , <b>2008</b> , 47, 674-83	11.6	308
43	Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2008</b> , 52, 2593-8	5.9	62
42	Pulmonary aspergillosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2008</b> , 29, 103-10	3.9	47
41	Aspergillosis <b>2008</b> , 181-199		1
40	The role of echinocandins, extended-spectrum azoles, and polyenes to treat opportunistic moulds and Candida. <i>Current Fungal Infection Reports</i> , <b>2007</b> , 1, 5-11	1.4	1
39	New guinea pig model of Cryptococcal meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2007</b> , 51, 3011-3	5.9	19
38	Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. <i>Clinical Infectious Diseases</i> , <b>2007</b> , 44, 2-12	11.6	640
37	Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. <i>Clinical Infectious Diseases</i> , <b>2007</b> , 44, 373-9	11.6	452

36	The role of echinocandins, extended-spectrum azoles, and polyenes to treat opportunistic moulds and <i>Candida</i> . <i>Current Infectious Disease Reports</i> , <b>2006</b> , 8, 442-8	3.9	5
35	Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. <i>Cancer</i> , <b>2006</b> , 107, 2888-97	6.4	173
34	Treatment of invasive aspergillosis: Polyenes, echinocandins, or azoles?. <i>Medical Mycology</i> , <b>2006</b> , 44, S357-S362	3.9	28
33	Standardization of an experimental murine model of invasive pulmonary aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2006</b> , 50, 3501-3	5.9	47
32	Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a Guinea pig model of invasive aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2006</b> , 50, 1567-9	5.9	24
31	Disruption of a nonribosomal peptide synthetase in <i>Aspergillus fumigatus</i> eliminates gliotoxin production. <i>Eukaryotic Cell</i> , <b>2006</b> , 5, 972-80		184
30	Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. <i>Journal of Infection</i> , <b>2006</b> , 53, 337-49	18.9	256
29	Advances and challenges in management of invasive mycoses. <i>Lancet, The</i> , <b>2005</b> , 366, 1013-25	40	178
28	Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis. <i>Pharmacotherapy</i> , <b>2005</b> , 25, 839-46	5.8	18
27	Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. <i>Clinical Infectious Diseases</i> , <b>2005</b> , 41, 1448-52	11.6	94
26	Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. <i>Clinical Infectious Diseases</i> , <b>2004</b> , 39, 1563-71	11.6	538
25	Antifungal combinations against <i>Candida albicans</i> biofilms in vitro. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2003</b> , 47, 3657-9	5.9	78
24	Combination antifungal therapy. <i>Pediatric Infectious Disease Journal</i> , <b>2003</b> , 22, 555-6	3.4	6
23	Antifungal resistance in pathogenic fungi. <i>Clinical Infectious Diseases</i> , <b>2002</b> , 35, 1073-80	11.6	198
22	In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of <i>Aspergillus</i> spp. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2002</b> , 46, 3039-41	5.9	157
21	Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2002</b> , 46, 2564-8	5.9	253
20	Nosocomial outbreak of <i>Exophiala jeanselmei</i> fungemia associated with contamination of hospital water. <i>Clinical Infectious Diseases</i> , <b>2002</b> , 34, 1475-80	11.6	58
19	New agents for treatment of invasive aspergillosis. <i>Clinical Infectious Diseases</i> , <b>2002</b> , 35, 367-9	11.6	13

18	Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2002</b> , 49, 353-7	5.1	30
17	In vitro activity of caspofungin against <i>Candida albicans</i> biofilms. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2002</b> , 46, 3591-6	5.9	239
16	Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. <i>New England Journal of Medicine</i> , <b>2002</b> , 347, 408-15	59.2	2596
15	Aspergillosis. Pathogenesis, clinical manifestations, and therapy. <i>Infectious Disease Clinics of North America</i> , <b>2002</b> , 16, 875-94, vi	6.5	253
14	Nosocomial fungemia due to <i>Exophiala jeanselmei</i> var. <i>jeanselmei</i> and a <i>Rhinocladiella</i> species: newly described causes of bloodstream infection. <i>Journal of Clinical Microbiology</i> , <b>2001</b> , 39, 514-8	9.7	53
13	Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. <i>Medicine (United States)</i> , <b>2000</b> , 79, 250-60	1.8	574
12	The epidemiology of non- <i>albicans</i> <i>Candida</i> in oropharyngeal candidiasis in HIV patients. <i>Special Care in Dentistry</i> , <b>2000</b> , 20, 178-81	1.7	44
11	Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2000</b> , 44, 2865-8	5.9	65
10	Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2000</b> , 44, 780-2	5.9	54
9	Practice guidelines for diseases caused by <i>Aspergillus</i> . Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , <b>2000</b> , 30, 696-709	11.6	641
8	Hospital Epidemiologic Surveillance for Invasive Aspergillosis: Patient Demographics and the Utility of Antigen Detection. <i>Infection Control and Hospital Epidemiology</i> , <b>1997</b> , 18, 104-108	2	51
7	<i>Aspergillus</i> and <i>Candida</i> Infections in Bone Marrow Transplantation. <i>Infectious Diseases in Clinical Practice</i> , <b>1997</b> , 6, 506-512	0.2	2
6	Hospital epidemiologic surveillance for invasive aspergillosis: patient demographics and the utility of antigen detection. <i>Infection Control and Hospital Epidemiology</i> , <b>1997</b> , 18, 104-8	2	29
5	Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. <i>Journal of Infectious Diseases</i> , <b>1996</b> , 174, 821-7	7	92
4	Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes. <i>Journal of Infectious Diseases</i> , <b>1989</b> , 159, 717-24	7	90
3	Antifungal therapy1344-1352		
2	Antifungal Therapy1423-1432		
1	Polymeric Iron Chelator with Enhanced Iron Affinity as a Broad-Spectrum Antifungal Agent. <i>ACS Applied Polymer Materials</i> ,	4.3	1

